Cargando…

18F-FDG PET/CT as predictive and prognostic factor in esophageal cancer treated with combined modality treatment

PURPOSE: [18F] fluorodeoxyglucose positron emission tomography/computed tomography ([18F] FDG-PET/CT) is used for diagnosis, staging, response assessment and prognosis prediction in different tumors, but its role in esophageal cancer is still debated. The aim of this study was to evaluate the role o...

Descripción completa

Detalles Bibliográficos
Autores principales: Krengli, Marco, Ferrara, Eleonora, Guaschino, Riccardo, Puta, Erinda, Turri, Lucia, Luciani, Ilaria, Sacchetti, Gian Mauro, Franco, Pierfrancesco, Brambilla, Marco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Nature Singapore 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9016048/
https://www.ncbi.nlm.nih.gov/pubmed/35275345
http://dx.doi.org/10.1007/s12149-022-01733-9
_version_ 1784688445252173824
author Krengli, Marco
Ferrara, Eleonora
Guaschino, Riccardo
Puta, Erinda
Turri, Lucia
Luciani, Ilaria
Sacchetti, Gian Mauro
Franco, Pierfrancesco
Brambilla, Marco
author_facet Krengli, Marco
Ferrara, Eleonora
Guaschino, Riccardo
Puta, Erinda
Turri, Lucia
Luciani, Ilaria
Sacchetti, Gian Mauro
Franco, Pierfrancesco
Brambilla, Marco
author_sort Krengli, Marco
collection PubMed
description PURPOSE: [18F] fluorodeoxyglucose positron emission tomography/computed tomography ([18F] FDG-PET/CT) is used for diagnosis, staging, response assessment and prognosis prediction in different tumors, but its role in esophageal cancer is still debated. The aim of this study was to evaluate the role of semiquantitative baseline PET parameters as possible prognostic and predictive factors in a series of esophageal carcinomas treated with combined modalities. METHODS: 43 patients with esophageal carcinoma were treated with chemoradiotherapy (CRT) followed by surgery in 20 cases and underwent pre-treatment 18F-FDG-PET/CT. Semiquantitative PET parameters were evaluated including Standardized Uptake Value (SUVmax e SUVmean), Metabolic Tumor Volume (MTV) and Total Lesion Glycolysis (TLG) with isocontour of 41 and 50%. Further variables analyzed were gender, primary tumor site, histological type, use of surgery, achievement of a radical resection and the type of chemotherapy regimen. The correlation of all variables with treatment response, loco-regional control (LR), Overall survival (OS) and Disease-Free Survival (DFS) was evaluated. RESULTS: SUVmax, SUVmean50 and SUVmean41 were significantly higher in node-positive cases and in squamous cell carcinomas. With respect to prognostic factors, MTV was found to be correlated with OS: patients with MTV41 < 11.32 cm(3) and MTV50 < 8.07 cm(3) (both p values = 0.04) showed better 3-year OS rates (33 vs. 20%). Further factors predicting a better prognosis were the use of surgery and radical resection (R0) (both p values < 0.01). CONCLUSIONS: Pre-treatment MTV values were significant prognostic factors for OS, together with the use of surgery and R0 resection in esophageal cancers treated with multimodal therapies.
format Online
Article
Text
id pubmed-9016048
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Nature Singapore
record_format MEDLINE/PubMed
spelling pubmed-90160482022-05-02 18F-FDG PET/CT as predictive and prognostic factor in esophageal cancer treated with combined modality treatment Krengli, Marco Ferrara, Eleonora Guaschino, Riccardo Puta, Erinda Turri, Lucia Luciani, Ilaria Sacchetti, Gian Mauro Franco, Pierfrancesco Brambilla, Marco Ann Nucl Med Original Article PURPOSE: [18F] fluorodeoxyglucose positron emission tomography/computed tomography ([18F] FDG-PET/CT) is used for diagnosis, staging, response assessment and prognosis prediction in different tumors, but its role in esophageal cancer is still debated. The aim of this study was to evaluate the role of semiquantitative baseline PET parameters as possible prognostic and predictive factors in a series of esophageal carcinomas treated with combined modalities. METHODS: 43 patients with esophageal carcinoma were treated with chemoradiotherapy (CRT) followed by surgery in 20 cases and underwent pre-treatment 18F-FDG-PET/CT. Semiquantitative PET parameters were evaluated including Standardized Uptake Value (SUVmax e SUVmean), Metabolic Tumor Volume (MTV) and Total Lesion Glycolysis (TLG) with isocontour of 41 and 50%. Further variables analyzed were gender, primary tumor site, histological type, use of surgery, achievement of a radical resection and the type of chemotherapy regimen. The correlation of all variables with treatment response, loco-regional control (LR), Overall survival (OS) and Disease-Free Survival (DFS) was evaluated. RESULTS: SUVmax, SUVmean50 and SUVmean41 were significantly higher in node-positive cases and in squamous cell carcinomas. With respect to prognostic factors, MTV was found to be correlated with OS: patients with MTV41 < 11.32 cm(3) and MTV50 < 8.07 cm(3) (both p values = 0.04) showed better 3-year OS rates (33 vs. 20%). Further factors predicting a better prognosis were the use of surgery and radical resection (R0) (both p values < 0.01). CONCLUSIONS: Pre-treatment MTV values were significant prognostic factors for OS, together with the use of surgery and R0 resection in esophageal cancers treated with multimodal therapies. Springer Nature Singapore 2022-03-11 2022 /pmc/articles/PMC9016048/ /pubmed/35275345 http://dx.doi.org/10.1007/s12149-022-01733-9 Text en © The Author(s) 2022, corrected publication 2022 https://creativecommons.org/licenses/by/4.0/ Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Article
Krengli, Marco
Ferrara, Eleonora
Guaschino, Riccardo
Puta, Erinda
Turri, Lucia
Luciani, Ilaria
Sacchetti, Gian Mauro
Franco, Pierfrancesco
Brambilla, Marco
18F-FDG PET/CT as predictive and prognostic factor in esophageal cancer treated with combined modality treatment
title 18F-FDG PET/CT as predictive and prognostic factor in esophageal cancer treated with combined modality treatment
title_full 18F-FDG PET/CT as predictive and prognostic factor in esophageal cancer treated with combined modality treatment
title_fullStr 18F-FDG PET/CT as predictive and prognostic factor in esophageal cancer treated with combined modality treatment
title_full_unstemmed 18F-FDG PET/CT as predictive and prognostic factor in esophageal cancer treated with combined modality treatment
title_short 18F-FDG PET/CT as predictive and prognostic factor in esophageal cancer treated with combined modality treatment
title_sort 18f-fdg pet/ct as predictive and prognostic factor in esophageal cancer treated with combined modality treatment
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9016048/
https://www.ncbi.nlm.nih.gov/pubmed/35275345
http://dx.doi.org/10.1007/s12149-022-01733-9
work_keys_str_mv AT krenglimarco 18ffdgpetctaspredictiveandprognosticfactorinesophagealcancertreatedwithcombinedmodalitytreatment
AT ferraraeleonora 18ffdgpetctaspredictiveandprognosticfactorinesophagealcancertreatedwithcombinedmodalitytreatment
AT guaschinoriccardo 18ffdgpetctaspredictiveandprognosticfactorinesophagealcancertreatedwithcombinedmodalitytreatment
AT putaerinda 18ffdgpetctaspredictiveandprognosticfactorinesophagealcancertreatedwithcombinedmodalitytreatment
AT turrilucia 18ffdgpetctaspredictiveandprognosticfactorinesophagealcancertreatedwithcombinedmodalitytreatment
AT lucianiilaria 18ffdgpetctaspredictiveandprognosticfactorinesophagealcancertreatedwithcombinedmodalitytreatment
AT sacchettigianmauro 18ffdgpetctaspredictiveandprognosticfactorinesophagealcancertreatedwithcombinedmodalitytreatment
AT francopierfrancesco 18ffdgpetctaspredictiveandprognosticfactorinesophagealcancertreatedwithcombinedmodalitytreatment
AT brambillamarco 18ffdgpetctaspredictiveandprognosticfactorinesophagealcancertreatedwithcombinedmodalitytreatment